awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q27853084-5D797135-1681-4754-91A5-9C56B2EE1767
Q27853084-5D797135-1681-4754-91A5-9C56B2EE1767
BestRank
Statement
http://www.wikidata.org/entity/statement/Q27853084-5D797135-1681-4754-91A5-9C56B2EE1767
Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer.
P2860
Q27853084-5D797135-1681-4754-91A5-9C56B2EE1767
BestRank
Statement
http://www.wikidata.org/entity/statement/Q27853084-5D797135-1681-4754-91A5-9C56B2EE1767
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
eede8ff4e6c498955fa05463a100cb567b076c18
P2860
Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancer